170 related articles for article (PubMed ID: 32394126)
1. Preoperative Chemotherapy for Pancreatic Cancer Improves Survival and R0 Rate Even in Early Stage I.
Vega EA; Kutlu OC; Salehi O; James D; Alarcon SV; Herrick B; Krishnan S; Kozyreva O; Conrad C
J Gastrointest Surg; 2020 Oct; 24(10):2409-2415. PubMed ID: 32394126
[TBL] [Abstract][Full Text] [Related]
2. Intraoperative Pancreatic Neck Margin Assessment During Pancreaticoduodenectomy for Pancreatic Adenocarcinoma in the Era of Neoadjuvant Therapy: A Multi-institutional Analysis from the Central Pancreatic Consortium.
Kelly KN; Macedo FI; Seaton M; Wilson G; Hammill C; Martin RC; Maduekwe UN; Kim HJ; Maithel SK; Abbott DE; Ahmad SA; Kooby DA; Merchant NB; Datta J
Ann Surg Oncol; 2022 Sep; 29(9):6004-6012. PubMed ID: 35511392
[TBL] [Abstract][Full Text] [Related]
3. The impact of chemotherapy sequencing on resectable pancreatic cancer by stage.
Vega EA; Kutlu OC; Salehi O; Alarcon SV; Abudalou M; Kozyreva O; Krishnan S; Lee D; Freeman R; Conrad C
Surg Oncol; 2022 Mar; 40():101694. PubMed ID: 34973593
[TBL] [Abstract][Full Text] [Related]
4. Contemporary Reappraisal of Intraoperative Neck Margin Assessment During Pancreaticoduodenectomy for Pancreatic Ductal Adenocarcinoma: A Review.
Datta J; Willobee BA; Ryon EL; Shah MM; Drebin JA; Kooby DA; Merchant NB
JAMA Surg; 2021 May; 156(5):489-495. PubMed ID: 33533898
[TBL] [Abstract][Full Text] [Related]
5. Perioperative chemotherapy is associated with a survival advantage in early stage adenocarcinoma of the pancreatic head.
Lutfi W; Talamonti MS; Kantor O; Wang CH; Liederbach E; Stocker SJ; Bentrem DJ; Roggin KK; Winchester DJ; Marsh R; Prinz RA; Baker MS
Surgery; 2016 Sep; 160(3):714-24. PubMed ID: 27422328
[TBL] [Abstract][Full Text] [Related]
6. Survival outcomes of neoadjuvant therapy followed by radical resection versus upfront surgery for stage I-III pancreatic ductal adenocarcinoma: a retrospective cohort study.
Zou Y; Gao S; Yu X; Zhou T; Xie Y; Guo X; An R; Wang X; Zhao T; Chang A; Gao C; Yu J; Hao J
Int J Surg; 2023 Jun; 109(6):1573-1583. PubMed ID: 37132194
[TBL] [Abstract][Full Text] [Related]
7. Neoadjuvant and Adjuvant Treatments for Resectable and Borderline Resectable Pancreatic Ductal Adenocarcinoma: The Current Status of Pancreatic Ductal Adenocarcinoma Treatment in Japan.
Ei S; Takahashi S; Ogasawara T; Mashiko T; Masuoka Y; Nakagohri T
Gut Liver; 2023 Sep; 17(5):698-710. PubMed ID: 36843421
[TBL] [Abstract][Full Text] [Related]
8. Adjuvant Chemotherapy Associated with Survival Benefit Following Neoadjuvant Chemotherapy and Pancreatectomy for Pancreatic Ductal Adenocarcinoma: A Population-Based Cohort Study.
Kamarajah SK; White SA; Naffouje SA; Salti GI; Dahdaleh F
Ann Surg Oncol; 2021 Oct; 28(11):6790-6802. PubMed ID: 33786676
[TBL] [Abstract][Full Text] [Related]
9. Network meta-analysis comparing neoadjuvant chemoradiation, neoadjuvant chemotherapy and upfront surgery in patients with resectable, borderline resectable, and locally advanced pancreatic ductal adenocarcinoma.
Hu Q; Wang D; Chen Y; Li X; Cao P; Cao D
Radiat Oncol; 2019 Jul; 14(1):120. PubMed ID: 31291998
[TBL] [Abstract][Full Text] [Related]
10. Outcomes of Distal Pancreatectomy for Pancreatic Ductal Adenocarcinoma in the Netherlands: A Nationwide Retrospective Analysis.
de Rooij T; Tol JA; van Eijck CH; Boerma D; Bonsing BA; Bosscha K; van Dam RM; Dijkgraaf MG; Gerhards MF; van Goor H; van der Harst E; de Hingh IH; Kazemier G; Klaase JM; Molenaar IQ; Patijn GA; van Santvoort HC; Scheepers JJ; van der Schelling GP; Sieders E; Busch OR; Besselink MG;
Ann Surg Oncol; 2016 Feb; 23(2):585-91. PubMed ID: 26508153
[TBL] [Abstract][Full Text] [Related]
11. History of preoperative therapy for pancreatic cancer and the MD Anderson experience.
Gaskill CE; Maxwell J; Ikoma N; Kim MP; Tzeng CW; Lee JE; Katz MHG
J Surg Oncol; 2021 May; 123(6):1414-1422. PubMed ID: 33831256
[TBL] [Abstract][Full Text] [Related]
12. A single center experience in resectable pancreatic ductal adenocarcinoma : the limitations of the surgery-first approach. Critical review of the literature and proposals for practice update.
Dumont R; Puleo F; Collignon J; Meurisse N; Chavez M; Seidel L; Gast P; Polus M; Loly C; Delvenne P; Meunier P; Hustinx R; Deroover A; Detry O; Louis E; Martinive P; Van Daele D
Acta Gastroenterol Belg; 2017; 80(4):451-461. PubMed ID: 29560639
[TBL] [Abstract][Full Text] [Related]
13. Proposed preoperative risk factors for early recurrence in patients with resectable pancreatic ductal adenocarcinoma after surgical resection: A multi-center retrospective study.
Matsumoto I; Murakami Y; Shinzeki M; Asari S; Goto T; Tani M; Motoi F; Uemura K; Sho M; Satoi S; Honda G; Yamaue H; Unno M; Akahori T; Kwon AH; Kurata M; Ajiki T; Fukumoto T; Ku Y
Pancreatology; 2015; 15(6):674-80. PubMed ID: 26467797
[TBL] [Abstract][Full Text] [Related]
14. Survival impact of distal pancreatectomy with en bloc celiac axis resection combined with neoadjuvant chemotherapy for borderline resectable or locally advanced pancreatic body carcinoma.
Murakami Y; Nakagawa N; Kondo N; Hashimoto Y; Okada K; Seo S; Otsuka H
Pancreatology; 2021 Apr; 21(3):564-572. PubMed ID: 33526385
[TBL] [Abstract][Full Text] [Related]
15. Factors Predicting Response, Perioperative Outcomes, and Survival Following Total Neoadjuvant Therapy for Borderline/Locally Advanced Pancreatic Cancer.
Truty MJ; Kendrick ML; Nagorney DM; Smoot RL; Cleary SP; Graham RP; Goenka AH; Hallemeier CL; Haddock MG; Harmsen WS; Mahipal A; McWilliams RR; Halfdanarson TR; Grothey AF
Ann Surg; 2021 Feb; 273(2):341-349. PubMed ID: 30946090
[TBL] [Abstract][Full Text] [Related]
16. Does a Laparoscopic Approach to Distal Pancreatectomy for Cancer Contribute to Optimal Adjuvant Chemotherapy Utilization?
Salehi O; Vega EA; Kutlu OC; Krishnan S; Sleeman D; De La Cruz Munoz N; Alarcon SV; Kazakova V; Kozyreva O; Conrad C
Ann Surg Oncol; 2021 Dec; 28(13):8273-8280. PubMed ID: 34125349
[TBL] [Abstract][Full Text] [Related]
17. The Addition of Postoperative Chemotherapy is Associated with Improved Survival in Patients with Pancreatic Cancer Treated with Preoperative Therapy.
Roland CL; Katz MH; Tzeng CW; Lin H; Varadhachary GR; Shroff R; Javle M; Fogelman D; Wolff RA; Vauthey JN; Crane CH; Lee JE; Fleming JB
Ann Surg Oncol; 2015 Dec; 22 Suppl 3(Suppl 3):S1221-8. PubMed ID: 26350371
[TBL] [Abstract][Full Text] [Related]
18. Preceding Systemic Chemotherapy for Patients with Pancreatic Ductal Adenocarcinoma with Positive Peritoneal Cytology Provides Survival Benefit Compared with Up-Front Surgery.
Ariake K; Mizuma M; Motoi F; Maeda S; Morikawa T; Ishida M; Ohtsuka H; Aoki S; Miura T; Takadate T; Nakagawa K; Kamei T; Unno M
Ann Surg Oncol; 2021 Oct; 28(11):6246-6254. PubMed ID: 33611747
[TBL] [Abstract][Full Text] [Related]
19. Impact of Margin Status on Survival in Patients with Pancreatic Ductal Adenocarcinoma Receiving Neoadjuvant Chemotherapy.
Schmocker RK; Delitto D; Wright MJ; Ding D; Cameron JL; Lafaro KJ; Burns WR; Wolfgang CL; Burkhart RA; He J
J Am Coll Surg; 2021 Apr; 232(4):405-413. PubMed ID: 33338577
[TBL] [Abstract][Full Text] [Related]
20. Impact of hypofractionated and standard fractionated chemoradiation before pancreatoduodenectomy for pancreatic ductal adenocarcinoma.
Cloyd JM; Crane CH; Koay EJ; Das P; Krishnan S; Prakash L; Snyder RA; Varadhachary GR; Wolff RA; Javle M; Shroff RT; Fogelman D; Overman M; Wang H; Maitra A; Lee JE; Fleming JB; Katz MH
Cancer; 2016 Sep; 122(17):2671-9. PubMed ID: 27243381
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]